Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Chris Lange | May 14, 2015 at 12:00 PM EDT

AcelRX Takes Flight With New Department of Defense Contract

AcelRX announced that it entered into a contract with the U.S. Army Medical Research and Material Command within the Department…

Lee Jackson | May 14, 2015 at 9:20 AM EDT

Analyst Issues 5 Potential Biotech Buyout Candidates

Cowen sees the potential for super-mergers in biotech, as well as a large group of smaller targets that may be…

Chris Lange | May 13, 2015 at 2:15 PM EDT

Are Problems at Orexigen Still Just Getting Started?

Orexigen Therapeutics shares plunge after termination of cardiovascular outcomes study of the obesity drug Contrave.

Chris Lange | May 12, 2015 at 3:58 PM EDT

Why the DepoMed Drop Is a Gross Overreaction

ThinkstockSometimes, or lots of times, investors and markets take things a little too far. For instance, a stock might overreact,…

Chris Lange | May 12, 2015 at 1:40 PM EDT

Could This Speculative Biotech More Than Triple?

Oppenheimer sees an upside of about triple the current share price of Tokai Pharmaceuticals, based on what it has coming…

Chris Lange | May 12, 2015 at 10:45 AM EDT

Why This Study May Have Saved Pain Therapeutics

Pain Therapeutics has announced top-line results for an FDA Category 3 Human Abuse Potential Study with Remoxy Extended-Release Capsules CII.

Chris Lange | May 12, 2015 at 9:50 AM EDT

Short Sellers Keep Strong Bets Against Big Pharma

The April 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short…

Lee Jackson | May 12, 2015 at 8:20 AM EDT

4 Biotech Stocks Could Have Big Upside Before Russell Index Changes

Credit Suisse expects that biotech stocks will see the most promotions in the coming rebalance of the Russell Indexes.

Chris Lange | May 12, 2015 at 8:05 AM EDT

Short Sellers Start to Get Nervous on Biotech

The short interest data are out for the April 30 settlement date, and for most of the selected biotech stocks,…

Jon C. Ogg | May 11, 2015 at 3:04 PM EDT

GSK Takes Aim at AIDS/HIV Cure, Funding Company With University of North Carolina at Chapel Hill

ThinkstockAny time that you hear about new drugs and medical treatments, they tend to be around ongoing treatments rather than…

Jon C. Ogg | May 9, 2015 at 9:45 AM EDT

4 Speculative Biotechs With Huge Analyst Targets

Among speculative small-cap biotechs, analyst calls are often accompanied with upside price targets of 50%, 100% or even 200%. This…

Chris Lange | May 8, 2015 at 11:00 AM EDT

What to Make of MannKind Earnings

Biotech company MannKind reported its first-quarter financial results after the markets closed Thursday.

Lee Jackson | May 8, 2015 at 9:20 AM EDT

4 Pharmaceutical Companies Leading the Breast Cancer Fight

In a new report, the RBC team focused on the companies that are making the most progress with treatments for…

Lee Jackson | May 7, 2015 at 8:30 AM EDT

Why These 4 Biotech Stocks Could Be the Next Buyout Targets

A new research note from SunTrust Robinson Humphrey mentions four stocks that they think could possibly get swept up in…

Chris Lange | May 6, 2015 at 1:20 PM EDT

Is the PlasmaTech Bio Rally Sustainable?

Wednesday morning, PlasmaTech Bio announced that it has entered into a definitive agreement to acquire Abeona Therapeutics.

1 … 262 263 264 265 266 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

AcelRX Takes Flight With New Department of Defense Contract

Analyst Issues 5 Potential Biotech Buyout Candidates

Are Problems at Orexigen Still Just Getting Started?

Why the DepoMed Drop Is a Gross Overreaction

Could This Speculative Biotech More Than Triple?

Why This Study May Have Saved Pain Therapeutics

Short Sellers Keep Strong Bets Against Big Pharma

4 Biotech Stocks Could Have Big Upside Before Russell Index Changes

Short Sellers Start to Get Nervous on Biotech

GSK Takes Aim at AIDS/HIV Cure, Funding Company With University of North Carolina at Chapel Hill

4 Speculative Biotechs With Huge Analyst Targets

What to Make of MannKind Earnings

4 Pharmaceutical Companies Leading the Breast Cancer Fight

Why These 4 Biotech Stocks Could Be the Next Buyout Targets

Is the PlasmaTech Bio Rally Sustainable?

After Reviewing Every International Developed Market ETF These 3 Cover Japan and Europe Better Than Anything Else

Emerging Markets Are Delivering Over 22 Percent Returns and Most American Investors Are Missing It Entirely

Why SOXX’s Next 12 Months Hinge on Five Tech Giants’ Capex Decisions

The RMD Trap: How a Single $95,000 Withdrawal Blindsided a 73-Year-Old's Medicare Costs

The Roth Conversion That Added $999.60 to a Retiree's Medicare Bill...Two Years Later

After Reviewing Every International Developed Market ETF These 3 Cover Japan and Europe Better Than Anything Else

Emerging Markets Are Delivering Over 22 Percent Returns and Most American Investors Are Missing It Entirely

Health and Healthcare Articles

All Health and Healthcare Articles

AcelRX Takes Flight With New Department of Defense Contract

Analyst Issues 5 Potential Biotech Buyout Candidates

Are Problems at Orexigen Still Just Getting Started?

Why the DepoMed Drop Is a Gross Overreaction

Could This Speculative Biotech More Than Triple?

Why This Study May Have Saved Pain Therapeutics

Short Sellers Keep Strong Bets Against Big Pharma

4 Biotech Stocks Could Have Big Upside Before Russell Index Changes

Short Sellers Start to Get Nervous on Biotech

GSK Takes Aim at AIDS/HIV Cure, Funding Company With University of North Carolina at Chapel Hill

4 Speculative Biotechs With Huge Analyst Targets

What to Make of MannKind Earnings

4 Pharmaceutical Companies Leading the Breast Cancer Fight

Why These 4 Biotech Stocks Could Be the Next Buyout Targets

Is the PlasmaTech Bio Rally Sustainable?

After Reviewing Every International Developed Market ETF These 3 Cover Japan and Europe Better Than Anything Else

Emerging Markets Are Delivering Over 22 Percent Returns and Most American Investors Are Missing It Entirely

Why SOXX’s Next 12 Months Hinge on Five Tech Giants’ Capex Decisions

Featured Reads

The RMD Trap: How a Single $95,000 Withdrawal Blindsided a 73-Year-Old's Medicare Costs

The Roth Conversion That Added $999.60 to a Retiree's Medicare Bill...Two Years Later